{"body":"<ol><li>Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/331697\">https:\/\/apps.who.int\/iris\/handle\/10665\/331697<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Cascade data use manual: to identify gaps in HIV and health services for programme improvement Geneva: World Health Organization; 2018 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/273119\">https:\/\/apps.who.int\/iris\/handle\/10665\/273119<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Surveillance of antiretroviral therapy: what's new in person-centred HIV patient and antiretroviral drug toxicity monitoring. Technical brief. Geneva: World Health Organization; 2020 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/333000\">https:\/\/apps.who.int\/iris\/handle\/10665\/333000<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Erad. 2019;5:41-3.<\/li>&#13;\n\t<li>Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381:827- 40.<\/li>&#13;\n\t<li>Consolidated strategic information guidelines for HIV in the health sector. Geneva: World Health Organization; 2015 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/164716\">https:\/\/apps.who.int\/iris\/handle\/10665\/164716<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Consolidated guidelines on person-centred HIV patient monitoring and case surveillance. Geneva: World Health Organization; 2017 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/255702\">https:\/\/apps.who.int\/iris\/handle\/10665\/255702<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Transition to new antiretroviral drugs in HIV programmes: clinical and programmatic considerations. Geneva: World Health Organization; 2017 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/255887\">https:\/\/apps.who.int\/iris\/handle\/10665\/255887<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>WHO implementation tool for monitoring the toxicity of new antiretroviral and antiviral medicines in HIV and viral hepatitis programmes Geneva: World Health Organization; 2018 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/273053\">https:\/\/apps.who.int\/iris\/handle\/10665\/273053<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>WHO implementation tool for pre-exposure prophylaxis (PrEP) for HIV infection. Module 5: Monitoring and evaluation. Geneva: World Health Organization; 2018 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/279834\">https:\/\/apps.who.int\/iris\/handle\/10665\/279834<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>HIV drug resistance report. Geneva: World Health Organization; 2019 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/325891\">https:\/\/apps.who.int\/iris\/handle\/10665\/325891<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Bertagnolio S, Hermans L, Jordan MR, Avila-Rios S, Iwuji C, Derache A et al. Clinical impact of pretreatment human immunodeficiency virus drug resistance in people initiating nonnucleoside reverse transcriptase inhibitor-containing antiretroviral therapy: a systematic review and meta-analysis. J Infect Dis. doi: 10.1093\/infdis\/jiaa683.<\/li>&#13;\n\t<li>HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis. Concept note. Geneva: World Health Organization; 2020 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/336543\">https:\/\/apps.who.int\/iris\/handle\/10665\/336543<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Global action plan on HIV drug resistance 2017-2021. Geneva: World Health Organization; 2017 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/255883\">https:\/\/apps.who.int\/iris\/handle\/10665\/255883<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Preventing and responding to HIV drug resistance in the African Region: regional action plan Geneva: World Health Organization; 2019 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/312176\">https:\/\/apps.who.int\/iris\/handle\/10665\/312176<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>HIV drug resistance surveillance [website]. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance\">https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance\/hiv-drug-resistance-surveillance<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Surveillance of HIV drug resistance in adults receiving ART [website]. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance\">https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance\/hiv-drug-resistance-surveillance\/ surveillance-of-acquired-hiv-drug-resistance-in-populations-receiving-art<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Surveillance of HIV drug resistance in children newly diagnosed with HIV by early infant diagnosis. Concept note. Geneva: World Health Organization; 2017 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/259732\">https:\/\/apps.who.int\/iris\/handle\/10665\/259732<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Surveillance of HIV drug resistance in populations initiating antiretroviral therapy (pre\u00adtreatment HIV drug resistance). Concept note. Geneva: World Health Organization; 2014 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/112802\">https:\/\/apps.who.int\/iris\/handle\/10665\/112802<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>WHO HIVResNet HIV drug resistance laboratory operational framework. 2nd ed. Geneva: World Health Organization; 2020 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/336169\">https:\/\/apps.who.int\/iris\/handle\/10665\/336169<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>HIV drug resistance surveillance. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/204471\">https:\/\/apps.who.int\/iris\/handle\/10665\/204471<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>HIV drug resistance [website]. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance\">https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance<\/a>, accessed 1 June 2021).<\/li>&#13;\n<\/ol>","title":"References","nid":635,"vid":2660,"created":1632394925,"changed":1632395087,"field_content_type":{"tid":1,"name":"Content","class":"content"}}